Vista Gel Hypromellose USP 0.3% w/v, Eye Drops Dry Eye Relief Lubricating Gel, 10 ml. (1/3 fl. oz...
FDA Drug Recall #D-0347-2026 — Class II — December 31, 2025
Recall Summary
| Recall Number | D-0347-2026 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 31, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Wizcure Pharmaa Private Limited |
| Location | Bhiwadi, N/A |
| Product Type | Drugs |
| Quantity | 17,280 cartons |
Product Description
Vista Gel Hypromellose USP 0.3% w/v, Eye Drops Dry Eye Relief Lubricating Gel, 10 ml. (1/3 fl. oz), Wizcure Pharmaa PVT. LTD, H-881, Phase-3, RIICO Industrial Area, Bhiwadi-301019, India, Manufactured for and distributed by: hi-health, 15207 N. 75th Street, Suite #104, Scottsdale, AZ, 85260, NDC 77790-002-10.
Reason for Recall
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Distribution Pattern
Distributed Nationwide in the USA
Lot / Code Information
All lots
Other Recalls from Wizcure Pharmaa Private Limited
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0352-2026 | Class II | BioGlo Fluorescein Sodium Ophthalmic Strips USP... | Dec 31, 2025 |
| D-0351-2026 | Class II | Bio Glo Fluorescein Sodium Ophthalmic Strips US... | Dec 31, 2025 |
| D-0346-2026 | Class II | Vista Tears Polyethylene Glycol 400 0.4% w/v, P... | Dec 31, 2025 |
| D-0349-2026 | Class II | Vista Gonio Eye Lubricant, Hypromellose Ophthal... | Dec 31, 2025 |
| D-0348-2026 | Class II | Vista Meibo Tears Propylene Glycol 0.6% w/v Eye... | Dec 31, 2025 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.